Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07321093 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Study acronym: MUSCAT
StatusRecruiting
PhasePhase 3
SponsorBiocad
Started2025-11-01
View on ClinicalTrials.gov ↗
Biocad
26 trials monitored
See all monitored trials
Multiple Sclerosis
987 trials monitored
See 31 trials at risk
The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Trial Details
NCT Number NCT07321093
Lead Sponsor Biocad
Conditions Relapsing-remitting Multiple Sclerosis (RRMS)
Enrollment 292 participants
Start Date 2025-11-01
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-06